Patient-reported outcomes with nivolumab plus cabozantinib in advanced kidney cancer

Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib have been published in The Lancet Oncology this week. Previous trial results have shown that the nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice as many previously untreated renal cell carcinoma (RCC) patients responded […]

read more

Cabozantinib after progression of kidney cancer improves survival

In a recent study, the use of cabozantinib after progression of renal cell carcinoma (RCC) was assessed. Forty-five (45) patients continued with treatment with cabozantinib after their disease had progressed, and 44 patients switched to cabozantinib. Nearly 60% of patients had been treated with two or more prior treatments. Of these patients, most (85%) had […]

read more

Cabozantinib for the treatment of kidney cancer brain metastases

Brain metastases resulting from the spread of renal cell carcinoma (RCC) are especially difficult to treat because drugs are prevented from getting to the brain by a membrane called the blood-brain barrier. Also, patients with brain metastases from RCC are not allowed in most clinical trials, and there is an unmet need for treatment of […]

read more

SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of the combination of cabozantinib (a vascular endothelial growth factor (VEGF) inhibitor) plus nivolumab (an immunotherapy) for use by NHS Scotland for the treatment of untreated people with advanced renal cell carcinoma (RCC). The approval was based on the results from a phase 3 study, which […]

read more

Cabozanitinib in combination with atezolizumab for advanced kidney cancer

This phase Ib study reports the results of a combination of cabozantinib plus atezolizumab in people with advanced clear cell and non–clear cell renal cell carcinoma (RCC). The number and nature of side effects to the 40 mg and 60 mg dose of cabozantinib were similar. Around two thirds of patients reported side effects to […]

read more

ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC

Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in several changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks the action of HIF-2α. This […]

read more

ESMO 2021: Cabozantinib for collecting duct carcinoma – the BONSAI study

Metastatic collecting duct carcinoma is an aggressive form of RCC, which is poorly researched and understood. There is an unmet need for an effective treatment for these patients, and very few clinical trials allow these patients to take part. This single centre, phase 2 trial tested cabozantinib in untreated patients with collecting duct carcinoma that […]

read more

Cabozantinib in pretreated patients with sarcomatoid kidney cancer

Sarcomatoid renal cell carcinoma (sRCC) is a rare and aggressive form of RCC in which the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). Patients with metastatic RCC with sarcomatoid features are difficult to treat and do not respond well to anti-angiogenic targeted therapy, such as sunitinib and pazopanib. This real […]

read more

ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib

Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib were presented a the American Society for Clinical Oncology (ASCO) Annual Meeting over the weekend. The nivolumab/cabozantinib combination doubled the average time to when the treatment stopped working and the cancer started growing again (progression-free survival) compared to sunitinib and nearly twice […]

read more

ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer

The cabozantinib/nivolumab combination has been shown to be effective at improving survival in patients with metastatic clear cell renal cell carcinoma (RCC) in a phase 3 trial. This poster presentation from the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend reports the results of a phase 2 trial of cabozantinib/nivolumab in patients […]

read more
Showing 1 to 10 of 90 results
  TOP